Kirchner, Thomas
German Cancer Research Center · Deutsches Konsortium für Translationale Krebsforschung · Pathologisches Institut · Ludwig-Maximilians-Universität München
10 papers on CoChatORCID 0000-0001-5226-6407
Most cited papers
- Verified
gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis
Bollrath, J., Phesse, T. J., von Burstin, V. A., Putoczki, T., Bennecke, M., Bateman, T., Nebelsiek, T., Lundgren-May, T., Canli, Ö., Schwitalla, S., et al. (2009) · Cancer Cell
Cytokine Signaling Pathways and InteractionsNF-κB Signaling Pathways
Cited by 946
- Verified
FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab for Metastatic Colorectal Cancer (FIRE-3): A Post-Hoc Analysis of Tumour Dynamics in the Final RAS Wild-Type Subgroup of This Randomised Open-Label Phase 3 Trial
Stintzing, S., Modest, D. P., Rossius, L., Lerch, M. M., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., et al. (2016) · The Lancet Oncology
Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments
Cited by 420
- Verified
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Neumann, J., Zeindl-Eberhart, E., Kirchner, T., & Jung, A. (2009) · Pathology - Research and Practice
Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer
Cited by 361
- Verified
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
Modest, D. P., Ricard, I., Heinemann, V., Hegewisch-Becker, S., Schmiegel, W., Porschen, R., Stintzing, S., Graeven, U., Arnold, D., von Weikersthal, L. F., et al. (2016) · Annals of Oncology
Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments
Cited by 351
- Verified
Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors
Schwitalla, S., Ziegler, P. K., Horst, D., Becker, V., Kerle, I., Begus-Nahrmann, Y., Lechel, A., Rudolph, K. L., Langer, R., Slotta-Huspenina, J., et al. (2013) · Cancer Cell
Cancer-related Molecular PathwaysGenetic factors in colorectal cancer
Cited by 296
- Verified
The Invasion Front of Human Colorectal Adenocarcinomas Shows Co-Localization of Nuclear β-Catenin, Cyclin D1, and p16INK4A and Is a Region of Low Proliferation
Jung, A., Schrauder, M., Oswald, U., Knoll, C., Sellberg, P., Palmqvist, R., Niedobitek, G., Brabletz, T., & Kirchner, T. (2001) · The American Journal of Pathology
Wnt/β-catenin signaling in development and cancerGenetic factors in colorectal cancer
Cited by 217
- Verified
Ink4a/Arf and Oncogene-Induced Senescence Prevent Tumor Progression during Alternative Colorectal Tumorigenesis
Bennecke, M., Kriegl, L., Bajbouj, M., Retzlaff, K., Robine, S., Jung, A., Arkan, M. C., Kirchner, T., & Greten, F. R. (2010) · Cancer Cell
Telomeres, Telomerase, and SenescenceGenetic factors in colorectal cancer
Cited by 186
- Verified
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer
Modest, D. P., Stintzing, S., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., et al. (2015) · Journal of Clinical Oncology
Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments
Cited by 121
- Verified
Up and downregulation of p16Ink4a expression in BRAF-mutated polyps/adenomas indicates a senescence barrier in the serrated route to colon cancer
Kriegl, L., Neumann, J., Vieth, M., Greten, F. R., Reu, S., Jung, A., & Kirchner, T. (2011) · Modern Pathology
Genetic factors in colorectal cancerTelomeres, Telomerase, and Senescence
Cited by 99
- Verified
KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer
Boeck, S., Jung, A., Laubender, R. P., Neumann, J., Egg, R., Goritschan, C., Ormanns, S., Haas, M., Modest, D. P., Kirchner, T., et al. (2013) · Journal of Gastroenterology
Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment
Cited by 77
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free